| Literature DB >> 33445704 |
Anette Boklund1, Anne Sofie Hammer1, Michelle Lauge Quaade1, Thomas Bruun Rasmussen2, Louise Lohse2, Bertel Strandbygaard2, Charlotte Sværke Jørgensen2, Ann Sofie Olesen1, Freja Broe Hjerpe2, Heidi Huus Petersen3, Tim Kåre Jensen3, Sten Mortensen4, Francisco F Calvo-Artavia4, Stine Kjær Lefèvre4,5, Søren Saxmose Nielsen1, Tariq Halasa1, Graham J Belsham1, Anette Bøtner1,2.
Abstract
SARS-CoV-2 infection is the cause of COVID-19 in humans. In April 2020, SARS-CoV-2 infection in farmed mink (Neovision vision) occurred in the Netherlands. The first outbreaks in Denmark were detected in June 2020 in three farms. A steep increase in the number of infected farms occurred from September and onwards. Here, we describe prevalence data collected from 215 infected mink farms to characterize spread and impact of disease in infected farms. In one third of the farms, no clinical signs were observed. In farms with clinical signs, decreased feed intake, increased mortality and respiratory symptoms were most frequently observed, during a limited time period (median of 11 days). In 65% and 69% of farms, virus and sero-conversion, respectively, were detected in 100% of sampled animals at the first sampling. SARS-CoV-2 was detected, at low levels, in air samples collected close to the mink, on mink fur, on flies, on the foot of a seagull, and in gutter water, but not in feed. Some dogs and cats from infected farms tested positive for the virus. Chickens, rabbits, and horses sampled on a few farms, and wildlife sampled in the vicinity of the infected farms did not test positive for SARS-CoV-2. Thus, mink are highly susceptible to infection by SARS-CoV-2, but routes of transmission between farms, other than by direct human contact, are unclear.Entities:
Keywords: COVID-19, increased mortality; Neovision vision; SARS-CoV-2 prevalence; clinical signs; environment; seroprevalence
Year: 2021 PMID: 33445704 PMCID: PMC7828158 DOI: 10.3390/ani11010164
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 2.752